Brief: INmune Bio Presents New Biomarker And Feasibility Data From Phase 1b Study Supporting The Use Of XPro To Treat Alzheimer’s Disease At Clinical Trials

Inmune Bio

17/10/2023 13:47

Oct 17 (Reuters) - INmune Bio Inc  INMB.O :
    * INMUNE BIO INC. PRESENTS NEW BIOMARKER AND FEASIBILITY
DATA FROM
PHASE 1B STUDY SUPPORTING THE USE OF XPRO™ TO TREAT ALZHEIMER’S
DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD)
CONFERENCE
    * INMUNE BIO INC - ENROLLING AD PATIENTS INTO A GLOBAL,
BLINDED,
RANDOMIZED PHASE II TRIAL

Source text for Eikon:  ID:nGNXKRTNK 
Further company coverage:  INMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))